CSPC Pharmaceutical Group Ltd. Announces Clinical Trial Approval in China and U.S. for JMT106, a Promising Bispecific Fusion Protein Drug Targeting Advanced Solid Tumors
Reuters
May 19, 2025
CSPC Pharmaceutical Group Ltd. Announces Clinical Trial Approval in China and U.S. for JMT106, a Promising Bispecific Fusion Protein Drug Targeting Advanced Solid Tumors
CSPC Pharmaceutical Group Limited has announced the approval of a clinical trial for its bispecific fusion protein drug, JMT106, in China. The approval was granted by the National Medical Products Administration of the People's Republic of China. JMT106 targets GPC3 and interferon receptors, aiming to kill tumor cells while activating immune regulation within the tumor microenvironment. It is specifically designed to address advanced solid tumors, including hepatocellular carcinoma, squamous cell carcinoma of the lung, and ovarian cancer. Previously, the U.S. Food and Drug Administration (FDA) approved the drug for clinical trials in the U.S. in January 2024. Preclinical studies have shown that JMT106 has significant anti-tumor effects and a strong safety profile, suggesting potential clinical development value.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.